Our nested case‐control sample also gave us the ability to estimate the prostate cancer risk associated with NF‐κB and GDF‐15 expression in benign prostate, which apart from unique studies such as the Prostate Cancer Prevention Trial,49 could not be carried out in a prospective setting. This evidence concerns the gene NFKB1 and prostate carcinoma.